Clinical Trial

A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

Study acronym: COALITION
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an open label, multi-centre, phase Ib/II, parallel arm study evaluating the safety and tolerability of glofitamab in addition to backbone chemotherapy consisting of R-CHOP or polatuzumab vedotin-RCHP for younger patients with higher-risk Diffuse Large B-cell Lymphoma or High Grade B-Cell Lymphoma.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2021-06-03; most recent amendment 2024-08-08.
Status change: Recruiting → Active, Not Recruiting 2023-08-21
Status change: Not Yet Recruiting → Recruiting 2021-07-19
Trial Details
NCT Number NCT04914741
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Collaborators: Hoffmann-La Roche
Conditions Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Enrollment 80 participants
Start Date 2021-06-29
Primary Completion 2023-12-05 (estimated)
Study Completion 2025-07 (estimated)
Updated on ClinicalTrials.gov 2024-08-12